Asymmetry Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Asymmetry Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-166,099	Closed	-$2.2M	–	32
2016 Q4	$2.2M	Buy	166,099 +1,943	+1%	+$33.2K	4.09%	12
2016 Q3	$3.89M	Buy	164,156 +93,921	+134%	+$2.52M	6.76%	6
2016 Q2	$2.02M	Buy	70,235 +8,185	+13%	+$267K	3.71%	13
2016 Q1	$1.99M	Buy	62,050 +10,620	+21%	+$373K	5.18%	9
2015 Q4	$2.2M	Buy	51,430 +13,151	+34%	+$525K	3.33%	12
2015 Q3	$1.35M	Buy	+38,279	New	+$1.72M	3%	16

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Asymmetry Capital Management's IPXL Position: Q1 2017 in Review

Asymmetry Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q1 2017, closing a stake of 166,099 shares — an estimated $2.2M sold.

Asymmetry Capital Management first reported a position in IPXL in Q3 2015 and held it in 6 quarters. The position peaked at $3.89M in Q3 2016. 178 funds tracked by Wall St. Rank hold IPXL as of Q1 2017.

Asymmetry Capital Management reported no remaining Impax Laboratories, Inc. position as of Q1 2017 after selling out during the quarter.
Asymmetry Capital Management sold 166,099 Impax Laboratories, Inc. shares in Q1 2017, an estimated $2.2M.
Asymmetry Capital Management first reported a position in Impax Laboratories, Inc. in Q3 2015 and held it in 6 quarters.
Asymmetry Capital Management's Impax Laboratories, Inc. position peaked at $3.89M in Q3 2016.
178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2017.

Based on Asymmetry Capital Management's 13F filing for Q1 2017, filed 12 May 2017.